PharmEasy revenue, valuation and funding
PharmEasy reported revenue of ₹6,618.5 crore in FY26 (the year to March 2026), against ₹5,664.2 crore in FY24, with a net loss of ₹520 crore, per filings and statements as reported.
| Revenue (FY26) | ₹6,618.5 crore |
|---|---|
| Revenue (FY24) | ₹5,664.2 crore |
| Net loss (FY26) | ₹520 crore |
| Net loss (FY24) | ₹2,531 crore |
Figures from filings and statements as reported; the table below carries each year with its source.
PharmEasy key facts
- What it doesOnline pharmacy and health platform Story
- Founded2015 Profile
- HeadquartersMumbai
- Last round₹1,700 crore (about $193 million), Debentures (debt), Sep 2025 Profile
- StatusPrivate
PharmEasy revenue and profit by year
| Year | Revenue | Profit or loss | Expenses | Note | Source |
|---|---|---|---|---|---|
| FY26 | ₹6,618.5 crore | ₹520 crore loss | ₹7,146.7 crore | API Holdings (parent of PharmEasy), consolidated; revenue from operations, up 12.7%; total income ₹6,689.2 crore; FY25 left out because sources differ on its revenue and loss | Inc42, FY26 results |
| FY24 | ₹5,664.2 crore | ₹2,531 crore loss | API Holdings (parent of PharmEasy), consolidated; operating revenue, as shown with the FY25 results | Outlook Business, FY25 and debentures |
As reported for each financial year; where sources disagree the figure is left out rather than picked.
Funding rounds
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 2022 | Debentures (debt) | $300 million (₹2,220 crore) | Goldman Sachs | Inc42, PharmEasy's Uneasy State |
| 2023 | Rights issue (equity) | ₹1,300 crore from Ranjan Pai | Ranjan Pai, chairman of Manipal Group | Inc42, PharmEasy's Uneasy State |
| 2024 | Fundraise (equity) | ₹800 crore from Ranjan Pai's family office | Ranjan Pai's family office | Inc42, PharmEasy's Uneasy State |
| Sep 2025 | Debentures (debt) | ₹1,700 crore (about $193 million) | Lenders not named in the report | Outlook Business, FY25 and debentures |
Timeline
- 2015
- 2015 PharmEasy is founded Inc42, healthtech list
- 2021
- 2021 Plans an IPO to raise ₹6,250 crore, later withdrawn because of market volatility Inc42, PharmEasy's Uneasy State
- Jun 2021 Buys diagnostics firm Thyrocare for about $600 million Inc42, PharmEasy's Uneasy State
- 2022
- 2022 Raises $300 million (₹2,220 crore) through debentures from Goldman Sachs Inc42, PharmEasy's Uneasy State
- 2023
- 2023 Ranjan Pai invests ₹1,300 crore in the rights issue Inc42, PharmEasy's Uneasy State
- 2024
- 2024 Ranjan Pai's family office invests ₹800 crore Inc42, PharmEasy's Uneasy State
- 2025
- Sep 2025 API Holdings raises ₹1,700 crore through debentures to redeem earlier debentures Outlook Business, FY25 and debentures
- 2026
- Mar 2026 Launches a WomenCare category for women's health products and services Indian Startup News, WomenCare
- Aug 2026 Repays its ₹1,050 crore term loan after selling about 9.90% of Thyrocare; keeps 51.02% Entrepreneur India, debt repaidMoneycontrol, debt-free parent
- Oct 2026 Reports FY26 consolidated net loss of ₹520 crore, down 67%, on revenue of ₹6,618.5 crore Inc42, FY26 results
The short version
- PharmEasy is an online pharmacy and healthcare app in India: medicines delivered to the door, lab tests and doctor consultations. Indian Startup News, WomenCare
- Siddharth Shah, Dharmil Sheth, Dhaval Shah, Harsh Parekh and Hardik Dedhia are named as its co-founders. Inc42, PharmEasy's Uneasy State
- The app belongs to API Holdings, which also owns listed diagnostics firm Thyrocare and the B2B businesses Ascent and Aknamed. Inc42, FY26 resultsMoneycontrol, debt-free parent
- For FY26, API Holdings reported revenue from operations of ₹6,618.5 crore, up 12.7%, and a consolidated net loss of ₹520 crore, down 67% from a year earlier. Inc42, FY26 results
- In August 2026 it cleared a ₹1,050 crore term loan with proceeds from selling about 9.90% of Thyrocare and some internal cash, and it still holds 51.02% of Thyrocare. Entrepreneur India, debt repaidMoneycontrol, debt-free parent
- Management is aiming for profit outside Thyrocare by September 2027 and says it could still list, or merge with Thyrocare, later, per Moneycontrol. Moneycontrol, debt-free parent
- Backers include TPG, Prosus Ventures, Temasek, CDPQ and Eight Roads; Manipal Group chairman Ranjan Pai put in ₹1,300 crore in 2023 and ₹800 crore in 2024. Moneycontrol, debt-free parentInc42, PharmEasy's Uneasy State
- It bought Thyrocare in June 2021 for about $600 million, and its valuation later fell about 90% to $456 million, per Inc42. Inc42, PharmEasy's Uneasy State
- Inc42's 2026 healthtech list puts its total funding at $1.96 billion, with debt as its latest funding type. Inc42, healthtech list
Deals and partnerships
| When | With | What | Price | Source |
|---|---|---|---|---|
| Jun 2021 | TTThyrocare Technologies | Listed diagnostics company bought by API Holdings | About $600 million | Inc42, PharmEasy's Uneasy State |
| Aug 2026 | TTThyrocare Technologies (stake sale) | Docon Technologies sold about 9.90% of Thyrocare, keeping 51.02%; buyer not named | Not disclosed | Entrepreneur India, debt repaidMoneycontrol, debt-free parent |
Products
- Online pharmacy: Medicines delivered to the door, ordered by uploading a prescription in the app or through WhatsApp. Indian Startup News, WomenCare
- Lab tests and doctor consults: Diagnostic tests booked online and doctor consultations, with consultations starting at Rs 199. Indian Startup News, WomenCare
- WomenCare: Category launched in March 2026 for women's health needs such as fertility and PCOD care. Indian Startup News, WomenCare
- B2B supply: API Holdings also runs the B2B businesses Ascent and Aknamed. Inc42, FY26 results
People
- Siddharth Shah: Co-founder of PharmEasy. Inc42, PharmEasy's Uneasy State
- Dharmil Sheth: Co-founder of PharmEasy. Inc42, PharmEasy's Uneasy State
- Dhaval Shah: Co-founder of PharmEasy. Inc42, PharmEasy's Uneasy State
- Harsh Parekh: Co-founder of PharmEasy. Inc42, PharmEasy's Uneasy State
- Hardik Dedhia: Co-founder of PharmEasy. Inc42, PharmEasy's Uneasy State
- Rahul Guha: Managing director and CEO of API Holdings. Entrepreneur India, debt repaid
- Alok Kumar Jagnani: Whole-time director and group CFO of API Holdings. Entrepreneur India, debt repaid
Questions people ask about PharmEasy
What is PharmEasy's revenue?
API Holdings, the parent of PharmEasy, reported revenue from operations of ₹6,618.5 crore for FY26 (the year to March 2026), up 12.7% on the year before, with total income of ₹6,689.2 crore. These are consolidated figures for the whole group, including diagnostics arm Thyrocare, not for the PharmEasy app alone. Inc42, FY26 results
Is PharmEasy profitable?
No. API Holdings, the parent of PharmEasy, posted a consolidated net loss of ₹520 crore for FY26, 67% lower than the year before, on revenue from operations of ₹6,618.5 crore. Its chief executive has set September 2027 as the target for profit outside Thyrocare, per Moneycontrol on 5 October 2026. Inc42, FY26 resultsMoneycontrol, debt-free parent
What is PharmEasy's valuation?
Inc42 reports that PharmEasy's valuation fell about 90% to $456 million during its 2023 rights issue and the fundraises that followed in 2024. Ranjan Pai put ₹1,300 crore into the rights issue and ₹800 crore through his family office in 2024. No newer valuation event appears in the sources for this page. Inc42, PharmEasy's Uneasy State
Who owns PharmEasy?
PharmEasy is owned by API Holdings, a private group backed by TPG, Prosus Ventures, Temasek, CDPQ and Eight Roads, per Moneycontrol. Manipal Group chairman Ranjan Pai invested ₹1,300 crore in the 2023 rights issue and ₹800 crore through his family office in 2024, per Inc42. Through its unit Docon Technologies, API Holdings holds 51.02% of listed Thyrocare. Moneycontrol, debt-free parentInc42, PharmEasy's Uneasy StateEntrepreneur India, debt repaid
Is PharmEasy going for an IPO?
No new IPO filing is reported in the sources for this page. API Holdings, PharmEasy's parent, says it could still list, or merge with Thyrocare, later, after first reaching profit outside Thyrocare, a goal it sets for September 2027, per Moneycontrol on 5 October 2026. An earlier plan to raise ₹6,250 crore through an IPO in 2021 was withdrawn because of market volatility, per Inc42. Moneycontrol, debt-free parentInc42, PharmEasy's Uneasy State
Every line links to the article it came from, written in our own words. Not investment advice. Profile updated 2026-11-11.
Stories cover its results, news, stake sale and people. Sectors: Healthcare & Life Sciences. Based in Mumbai and Navi Mumbai. Stories run from 6 March 2026 to 12 October 2026.
The founders
Who put in money
Head to head: PharmEasy vs Tata 1mg →
Every story on PharmEasy
- PH
PharmEasy · Results · 12 October 2026 · ₹520 CrPharmEasy parent cuts FY26 loss 67%PharmEasy is an online pharmacy and diagnostics platform run by its parent company, API Holdings
- PH
PharmEasy · News · 5 October 2026PharmEasy parent clears debt, weighs IPO returnAPI Holdings owns the PharmEasy online pharmacy and the Ascent and Aknamed businesses, and is backed by TPG and other global funds
- PH
PharmEasy · Stake sale · 16 August 2026 · ₹986 croreAPI Holdings sells Thyrocare stake, repays debtAPI Holdings runs PharmEasy, an online pharmacy, and Thyrocare, a diagnostics chain
- PH
PharmEasy · People · 6 March 2026PharmEasy launches WomenCare category for women's healthPharmEasy is an online platform for medicines, lab tests, and doctor consultations
Read next on PharmEasy
For PharmEasy: add the “Featured on StopDown” badge
Put this on your website's press or media page. It links readers to PharmEasy on StopDown.

